Taylor Brooks, MD
Hematology & Oncology · Cleveland, OHNPI 1255838116
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.0%), food and beverage and education — rather than concentrated in one kind of arrangement. ADC Therapeutics America, Inc. accounts for 66.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $1,397 and has fallen 74.8% since, to $352 in 2025. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 17 payments — averaging $116.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$1K
- Genmab U.S., Inc.$251
- Genentech USA, Inc.$146
- Beone Medicines USA, Inc.$125
- Lilly USA, LLC$77
- Biotissue Holdings Inc.$41
- plus $17 from 1 others
Across 1 payment — averaging $33,536 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beone Medicines Ltd.$34K
What the payments were for
- Travel & lodging$98950%
- Food & beverage$91346%
- Education$774%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 7 | $1,323 |
| Genmab U.S., Inc. | 4 | $251 |
| Genentech USA, Inc. | 2 | $146 |
| Beone Medicines USA, Inc. | 1 | $125 |
| Lilly USA, LLC | 1 | $77 |
| Biotissue Holdings Inc. | 1 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$125
How this compares
$1,978 in reported general payments places this provider in the 45th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 12 | $160 |
| Prednisone | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.